ALNY - Alnylam kidney disorder therapy Oxlumo improves cardiac measures in new data from phase 3 trial

Alnylam Pharmaceuticals (NASDAQ:ALNY) said new analysis from a late-stage study of its drug Oxlumo (lumasiran) showed that the drug helped improve cardiac measures, calcium deposit levels and kidney stone events in patients with advanced primary hyperoxaluria type 1 (PH1). PH1 is a rare, genetic disease of the mainly affecting the kidneys, characterized by oxalate overproduction. High levels of oxalate crystals in the kidneys and urinary tract and can lead to formation of kidney stones, and may to lead to kidney failure, The company reported data from six-month primary analysis period of a phase 3 trial called ILLUMINATE-C of lumasiran. Alnylam previously said that treatment with lumasiran resulted in substantial reductions in plasma oxalate (POx) at six months. The company said new results showed that lumasiran helped improve cardiac measures, nephrocalcinosis (disorder in which high levels of calcium gets deposited in the kidneys) and kidney stone events; plus some patients treated with lumasiran experienced improvements in

For further details see:

Alnylam kidney disorder therapy Oxlumo improves cardiac measures in new data from phase 3 trial